Illumina, Inc

About Illumina, Inc.

Illumina, Inc. is a leading global biotechnology company that develops innovative tools and technologies for genetic analysis. Founded in 1998, the company has revolutionised the field of genomics by providing advanced sequencing and array-based solutions. With a mission to improve human health by unlocking the power of the genome, Illumina is at the forefront of genomic research and applications.

The company’s core activities include the development of next-generation sequencing (NGS) systems, which enable researchers to sequence DNA and RNA quickly and accurately. These technologies are essential for a wide range of applications, including cancer research, genetic disease studies, and personalised medicine.

Illumina’s product portfolio also includes bioinformatics software and services that help researchers analyse and interpret complex genomic data. By integrating hardware, software, and consumables, Illumina provides comprehensive solutions that empower scientists and healthcare professionals worldwide.

With a strong commitment to innovation, Illumina invests heavily in research and development, ensuring that it remains a leader in the rapidly evolving field of genomics. The company collaborates with academic institutions, healthcare providers, and pharmaceutical companies to advance genomic science and its applications.

Illumina operates globally, with a significant presence in the UK, where it contributes to the local economy and scientific community. The company is dedicated to fostering a culture of inclusivity and collaboration, driving advancements in genomics that benefit society as a whole.

As part of its vision, Illumina aims to make genomic information accessible to all, paving the way for breakthroughs in healthcare and personalised treatment options. Through its cutting-edge technology and unwavering commitment to quality, Illumina continues to shape the future of genomics.